Oncogenic RIT1 mutations in lung adenocarcinoma

@inproceedings{Berger2014OncogenicRM,
  title={Oncogenic RIT1 mutations in lung adenocarcinoma},
  author={Alice H. Berger and Marcin B Imielinski and F Duke and Jeremiah A Wala and Nir Kaplan and G-X Shi and Douglas A. Andres and Matthew L Meyerson},
  booktitle={Oncogene},
  year={2014}
}
Lung adenocarcinoma is comprised of distinct mutational subtypes characterized by mutually exclusive oncogenic mutations in RTK/RAS pathway members KRAS, EGFR, BRAF and ERBB2, and translocations involving ALK, RET and ROS1. Identification of these oncogenic events has transformed the treatment of lung adenocarcinoma via application of therapies targeted toward specific genetic lesions in stratified patient populations. However, such mutations have been reported in only ∼55% of lung… CONTINUE READING